IRD · NASDAQ
Opus Genetics (IRD) Stock Price & Fundamentals
Opus Genetics (IRD) closed at $668.72 on Oct 9, 2026, down 0.21% from the previous close of $670.12.
Share price, past year
1Y +7.49%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $668.72 |
| Sep 30, 2026 | $658.56 |
| Aug 31, 2026 | $641.93 |
| Jul 31, 2026 | $651.37 |
| Jun 30, 2026 | $636.16 |
| May 29, 2026 | $629.07 |
| Apr 30, 2026 | $640.22 |
| Mar 31, 2026 | $602.52 |
| Feb 27, 2026 | $598.94 |
| Jan 30, 2026 | $610.57 |
| Dec 31, 2025 | $592.56 |
| Nov 28, 2025 | $578.26 |
| Oct 31, 2025 | $589.82 |
Key statistics
- Market cap
- $55.27B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.26
- Revenue (TTM)
- $9.86M
- Net income (TTM)
- −$107.61M
- Shares outstanding
- 82.6M
- Dividend yield
- —
- 52-week range
- $567.47 – $675.69
Opus Genetics's market cap is $55.27B, based on a share price of $668.72 and 82.6M shares outstanding as of Jun 30, 2026.
Financials
Opus Genetics reported revenue of $14.20M for fiscal 2025, up 29.15% from fiscal 2024.
Opus Genetics reported a net loss of $49.59M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $14.20M | +29.2% | −$49.59M | −349.3% | −$0.80 | — |
| FY2024ended Dec 31, 2024 | $10.99M | −42.3% | −$57.53M | −523.4% | −$2.15 | — |
| FY2023ended Dec 31, 2023 | $19.05M | −52.2% | −$9.99M | −52.4% | −$0.46 | — |
| FY2022ended Dec 31, 2022 | $39.85M | +6,665.7% | $17.89M | 44.9% | $0.87 | — |
| FY2021ended Dec 31, 2021 | $589.00K | — | −$56.69M | −9,625.3% | −$3.82 | — |
| FY2020ended Dec 31, 2020 | $0.00 | −100.0% | −$24.62M | — | −$5.28 | −$6.80M |
| FY2019ended Dec 31, 2019 | $3.00M | — | −$6.17M | −205.6% | — | −$3.62M |
| FY2013ended Dec 31, 2013 | $0.00 | — | — | — | — | — |
| FY2012ended Dec 31, 2012 | $0.00 | — | — | — | — | — |
| FY2011ended Dec 31, 2011 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $755.00K | −$8.10M | −$0.14 |
| Q1 FY2026ended Mar 31, 2026 | $2.16M | −$65.54M | −$0.75 |
| Q4 FY2025ended Dec 31, 2025 | $3.87M | −$16.52M | — |
| Q3 FY2025ended Sep 30, 2025 | $3.08M | −$17.45M | −$0.25 |
| Q2 FY2025ended Jun 30, 2025 | $2.88M | −$7.42M | −$0.12 |
| Q1 FY2025ended Mar 31, 2025 | $4.37M | −$8.19M | −$0.24 |
| Q4 FY2024ended Dec 31, 2024 | $4.30M | −$35.14M | — |
| Q3 FY2024ended Sep 30, 2024 | $3.87M | −$7.53M | −$0.29 |
Company profile
- Name
- Opus Genetics, Inc.
- Ticker
- IRD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 8 Davis Drive, Suite 220, Durham, NC 27713
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001228627
Recent SEC filings
- Sep 11, 2026
- Sep 9, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 16, 2026
- Jun 16, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is Opus Genetics's stock price?
Opus Genetics (IRD) closed at $668.72 on Oct 9, 2026, down 0.21% from the previous close of $670.12.
What is Opus Genetics's market cap?
Opus Genetics's market cap is $55.27B, based on a share price of $668.72 and 82.6M shares outstanding as of Jun 30, 2026.
How much revenue does Opus Genetics make?
Opus Genetics reported revenue of $14.20M for fiscal 2025, up 29.15% from fiscal 2024.
Does Opus Genetics pay a dividend?
Opus Genetics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Opus Genetics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures